Cowen lifts Bavarian Nordic to "outperform" after recent monkeypox vaccine orders

A run of good news for the Danish vaccine maker has caught the attention of the US-based investment bank, which finds there are more prospects for long-term vaccine stockpiling on the horizon.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

US-based investment bank Cowen has changed its rating of Bavarian Nordic to ”outperform” from ”market perform,” Bloomberg News reports.

According to the media, the bank finds it likely that a need could arise for different countries facing the monkeypox outbreak to build vaccine stockpiles. Bavarian Nordic’s upgrades of its financial expectations on both Friday last week and Monday this week are also positive in the bank’s eyes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs